[HTML][HTML] Long-term immunosuppression management: opportunities and uncertainties
D Wojciechowski, A Wiseman - … Journal of the American Society of …, 2021 - journals.lww.com
The long-term management of maintenance immunosuppression in kidney transplant
recipients remains complex. The vast majority of patients are treated with the calcineurin
inhibitor tacrolimus as the primary agent in combination with mycophenolate, with or without
corticosteroids. A tacrolimus trough target 5–8 ng/ml seems to be optimal for rejection
prophylaxis, but long-term tacrolimus-related side effects and nephrotoxicity support the
ongoing evaluation of noncalcineurin inhibitor–based regimens. Current alternatives include …
recipients remains complex. The vast majority of patients are treated with the calcineurin
inhibitor tacrolimus as the primary agent in combination with mycophenolate, with or without
corticosteroids. A tacrolimus trough target 5–8 ng/ml seems to be optimal for rejection
prophylaxis, but long-term tacrolimus-related side effects and nephrotoxicity support the
ongoing evaluation of noncalcineurin inhibitor–based regimens. Current alternatives include …